Jahoda D, Nyc O, Pokorný D, Landor I, Krůta T, Sosna A
1st Orthopedic Clinic, 1st Medical Faculty, Charles University, 150 06 Prague, Czechia.
Folia Microbiol (Praha). 2007;52(3):281-5. doi: 10.1007/BF02931310.
During 1999-2005 we treated 15 patients with linezolid for relevant infections of locomotion apparatus (7 cases with endoprosthesis infection, 5x osteomyelitis and 3x another infection). With the exception of one case the antibiotic therapy was always combined with appropriate surgical intervention. Average period of linezolid administration was 26 d; linezolid was applied from the beginning intravenously on average for 10 d, and then orally for 16 d (average). There were no undesirable effects in the file. Success rate reached 86.6%. MRSA strains were proved by standard methods: growth on Mueller-Hinton agar with increased concentration of NaCl and 2 mg/L of oxacilline, and measuring inhibitory zones around cephoxitine disk. The sensitivity to other antibiotics was specified by disk-diffusion test; that to linezolid was verified by E-test. Linezolid represents a medical reserve for the treatment of multiresistant Gram-positive infections or for emergencies, when allergy onset, high toxicity risk, intolerance, etc. do not allow to use other, in vitro effective, antibiotics.
1999年至2005年期间,我们使用利奈唑胺治疗了15例运动器官相关感染患者(7例假体感染、5例骨髓炎和3例其他感染)。除1例患者外,抗生素治疗均始终联合适当的手术干预。利奈唑胺的平均给药期为26天;利奈唑胺平均从一开始静脉给药10天,然后口服给药16天。记录中未出现不良反应。成功率达到86.6%。耐甲氧西林金黄色葡萄球菌(MRSA)菌株通过标准方法鉴定:在含增加浓度氯化钠和2 mg/L苯唑西林的穆勒-欣顿琼脂上生长,并测量头孢西丁纸片周围的抑菌圈。对其他抗生素的敏感性通过纸片扩散试验确定;对利奈唑胺的敏感性通过E试验验证。当出现过敏反应、高毒性风险、不耐受等情况而不允许使用其他体外有效的抗生素时,利奈唑胺是治疗多重耐药革兰氏阳性感染或紧急情况的一种药物储备。